Prognosis Prediction Model After Upfront Surgery for Resectable Pancreatic Ductal Adenocarcinoma: A Multicenter Study (OS-HBP-2)
Kosei Takagi(Okayama Shoka University), Toshiyoshi Fujiwara(Okayama University), Kenta Sui(Okayama University), Takehiro Okabayashi(CHI Health), Daisuke Nobuoka(Fukuyama City Hospital), Tatsuo Matsuda(Okayama University Hospital), Susumu Shinoura(Okayama University), Kazuya Yasui(Okayama University), Hideki Aoki(Iwakuni Medical Center), Toru Kojima(Okayama Saiseikai General Hospital), Yoshikatsu Endo(Himeji Red Cross Hospital), Masashi Kimura(Matsuyama Shimin Hospital), Masaru Inagaki(Fukuyama Cardiovascular Hospital), Masayoshi Hioki(Fukuyama City Hospital), Ryuichi Yoshida(Okayama University)
Cited by 1
Related Papers
Phase I Trial of a Glypican-3–Derived Peptide Vaccine for Advanced Hepatocellular Carcinoma: Immunologic Evidence and Potential for Improving Overall Survival
|Clinical Cancer Research|2012|304
CSF1/CSF1R Signaling Inhibitor Pexidartinib (PLX3397) Reprograms Tumor-Associated Macrophages and Stimulates T-cell Infiltration in the Sarcoma Microenvironment
|Molecular Cancer Therapeutics|2021|258
Phase II study of the GPC3-derived peptide vaccine as an adjuvant therapy for hepatocellular carcinoma patients
|OncoImmunology|2016|178